FDA delays review of two drugs under the commissioner's voucher programme amid safety and efficacy concerns; Eli Lilly (LLY) and Sanofi (SAN FP) targeted
Newsquawk Staff ·
FDA delays review of two drugs under the commissioner's voucher programme amid safety and efficacy concerns; Eli Lilly (LLY) and Sanofi (SAN FP) targeted.
What it means
The FDA's delay of the review for two drugs associated with Eli Lilly and Sanofi signals significant safety and efficacy concerns, potentially impacting their market strategies and share prices. This delay may also suggest heightened scrutiny from regulators, which could affect investor sentiment in the pharmaceutical sector, particularly for these companies. Watch for broader implications in equity performance and any potential shifts in regulatory approaches within the industry.
- US officials have reportedly held up approval for American chipmaking equipment needed by SK Hynix (SKHY/000660 KS) to expand production in China, according to source reports
- Ceconomy (CEC GY) says all closing conditions for JD.com's (9618 HK) public takeover offer have been satisfied after receiving European Commission clearance under the EU Foreign Subsidies Regulation
- Saudi Aramco Q3 (SAR) adj. net 117.0bln (exp. 107.9bln)
- Automakers including GM (GM), Stellantis (STLA) and Volkswagen (VOW3 GY) urge US lawmakers to swiftly pass a permanent ban on Chinese vehicles when they return for the post-election session
- Japan asks Anthropic and OpenAI for more access to advanced AI models, Nikkei reports
Related headlines
- Didi Global (DIDI) has submitted a Hong Kong ride‑hailing licence application, according to Hong Kong Economic JournalOct 30
- Vale (VALE) Q3 (USD) net 1.26bln (prev. 2.4bln Y/Y), pro forma EBITDA 3.51bln (exp. 3.32bln), rev. 10.6bln (exp. 10.1bln), iron ore output 88.35mln tons (exp. 91.64mln tons)Oct 29
- Novo Nordisk (NOVOB DC/NVO) to present new CagriSema and Wegovy data at ObesityWeek 2026, including data on real-world treatment experience with the Wegovy pillOct 29
- China's gaming regulator approves 183 domestic games and 12 imported games in October (prev. 206 total in September)Oct 29
- BYD Electronic (0285 HK) 9-month 2026 (RMB): net profit -69.3% Y/Y to CNY 963mln, revenue +3.38% Y/Y 127.46bln Oct 29
- OpenAI’s Astra model becomes top distillation target for China’s AI labs, while Moonshot AI and DeepSeek utilise OpenAI’s Astra outputs for new models released this month, according to The InformationOct 29
- Silicon Motion (SIMO) Q3 (USD) EPS 4.35 (exp. 3.30), rev. 560mln (exp. 533mln)Oct 28
- Deutsche Telekom (DTE GY) is backing off on a merger with T-Mobile US (TMUS), according to reportsOct 28
- Genmab (GMAB/GMAB DC) announced positive topline results from the global Phase 3 LiGeR-HN1 trial evaluating petosemtamabOct 28
- Eli Lilly’s (LLY) retatrutide delivered greater A1C reduction and more than double the weight loss of Novo Nordisk’s (NOVOB DC) Ozempic at its highest approved dose in head-to-head trialOct 28
- TPG pursues USD 5bln acquisition of UK data centre group Ark, according to FTOct 28
- Syngenta targets at least a USD 66bln valuation in Hong Kong IPOOct 28
- HP (HPQ), Asus (2357 TT) and Acer (2353 TT) are shifting some PC production from Thailand and Vietnam back to China to combat soaring component costs driven by AI-related memory and storage shortages, reports Nikkei citing sourcesOct 27
- Universal Music Group (UMG NA) discusses going private with buyout firms, according to BloombergOct 26
- Japan's Sakana AI to build homegrown model to cut US and China reliance, reports NikkeiOct 26